MedPath

A quasi-randomized clinical trial of tapentadol versus oxycodone for initial control of moderate cancer-related pai

Phase 4
Conditions
Malignant neoplasm
Registration Number
JPRN-UMIN000018954
Lead Sponsor
Kansai Electric Power Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
54
Inclusion Criteria

Not provided

Exclusion Criteria

Patients with previously receiving strong opioid analgesic administration. Patient with severe cancer-related pain (NRS 9-10 and/or STAS-J 4)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath